MAPT and Alzheimer disease: Besides that treatment was extended during the progression of pathological and behavioral features (i.e., from 8 to 12–14 months of age), Se reduced aggregated tau-positive neurons in CA1 hippocampus and temporal auditory cortex in 3xTg-AD mice.